IL-33 deficiency suppresses alveolar bone loss in a ligature-induced periodontitis model

Biomed Res. 2023;44(1):9-16. doi: 10.2220/biomedres.44.9.

Abstract

Interleukin-33 (IL-33) is a member of the IL-1 cytokine family that has been studied primarily in the context of type 2 immune responses. Recent reports suggest that IL-33 also enhances the func- tions of various immune cells and contributes to the development of different inflammatory diseas- es. Interestingly, IL-33 and its receptor ST2 axis exerted either inhibitory or promotional effects on alveolar bone loss in various periodontitis models. Using a mouse model of ligature-induced periodontitis, we found that the levels of mRNAs encoding IL-33 and other inflammatory cyto- kines (IL-1α, IL-1β, IL-6, and TNFα) were augmented in gingival tissues of wild-type (WT) mice, and that the alveolar bone loss amount was lower in IL-33-deficient than WT mice. The numbers and proportions of IFN-γ-producing CD8+ T and regulatory T cells were decreased while those of Th17 cells were increased in the draining lymph nodes of IL-33-deficient mice compared to WT mice. Additionally, the level of RNA encoding an osteoclastogenic molecule, i.e., receptor activa- tor of nuclear factor kappa-B ligand (RANKL), in ligated gingival tissue was higher in IL-33-defi- cient than WT mice. These results suggest that IL-33 is involved in alveolar bone loss in the ligature-induced periodontitis model, although IL-33 may inhibit osteoclast differentiation.

MeSH terms

  • Alveolar Bone Loss* / etiology
  • Alveolar Bone Loss* / pathology
  • Animals
  • Cytokines
  • Interleukin-33 / genetics
  • Mice
  • Osteogenesis
  • Periodontitis* / pathology
  • RANK Ligand / genetics
  • RANK Ligand / pharmacology

Substances

  • Interleukin-33
  • Cytokines
  • RANK Ligand